カテゴリ： GlobalData, アメリカ, 企業調査

Amgen Inc (AMGN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Amgen Inc (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012247
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：370
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 10
List of Figures 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
Amgen Inc, Medical Devices Deals, 2011 to YTD 2017 18
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Amgen Inc, Pharmaceuticals & Healthcare, Deal Details 26
Asset Purchase 26
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 26
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD479 Million 27
Amgen Completes Acquisition Of Dublin Sterile Plant From Pfizer 29
Amgen Reacquires Rights Of Its Products From Hypermarcas 31
Venture Financing 32
Immatics Biotech Raises USD58 Million in Series E Financing 32
SiteOne Therapeutics Raises USD15 Million in Series B Financing 33
Dezima Pharma Raises US$13 Million In Series A Financing 34
Dezima Pharma Raises Funds Through Seed Financing 35
Gamida Cell Raises US$10 Million In Series E Financing 36
Partnerships 38
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 38
Amgen Enters into Research Agreement with Boston Children’s Hospital 39
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 40
Amgen and Simcere Pharma Enter into Co-Development Agreement 41
Amgen and Array BioPharma Enter into Agreement 42
Elasmogen, Feldan Bio Enter into Agreement with Amgen 43
SiteOne Therapeutics Enters into R&D Agreement with Amgen 44
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 45
Nuevolution Enters into Research Agreement with Amgen 46
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 47
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 48
Amgen Forms Partnership with Advaxis 49
Amgen Enters into Agreement with Allergan 50
Amgen and Daiichi Sankyo Enter into Agreement 51
Flatiron Health Partners with Amgen 52
Amgen and Merck Enter into Agreement 53
Amgen Expands its Co-Development Agreement with Novartis 54
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen 55
Amgen Enters into Research Agreement with MD Anderson 56
Innovative Targeting Solutions Enters into Research Agreement with Amgen 57
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 58
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 60
Amgen and Astellas Pharma Form Joint Venture 61
Amgen Forms Joint Venture With Zhejiang Beta Pharma 62
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 64
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 65
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 66
Amgen Enters Into Co-Development Agreement With Astellas 67
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 68
PeptiDream Expands Drug Discovery Agreement with Amgen 69
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 70
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 71
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 72
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 73
Dako Enters Into Co-Development Agreement With Amgen 75
Dako Enters Into Co-Development Agreement With Amgen 76
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 77
Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 79
deCODE genetics Enters Into Research Agreement With Pfizer 80
Micromet Enters Into Research Agreement With Amgen For BiTE Antibodies 81
S*Bio Amends Collaboration With Onyx Pharma 82
Merger 83
AstraZeneca Rumored To Merge With Amgen 83
Licensing Agreements 84
Amgen Enters into Licensing Agreement with Carmot Therapeutics 84
Amgen Enters into Licensing Agreement with Ligand Pharma 85
Amgen Enters into Licensing Agreement with Immatics Biotech 86
Amgen Enters into Licensing Agreement with Teijin Pharma 87
Amgen Enters into Licensing Agreement with Arrowhead Pharma 88
Amgen Enters into Licensing Agreement with Xencor 89
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 90
FLX Bio Enters Into Licensing Agreement with Amgen 91
Celimmune Enters into Licensing Agreement with Amgen for AMG 714 92
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 93
Amgen Enters into Licensing Agreement with Kite Pharma 94
Cancer Research UK Enters into Licensing Agreement with Amgen 96
Amgen Expands its Licensing Agreement with Carmot Therapeutics 97
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 98
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 100
Atara Biotherapeutics Enters Into Licensing Agreement with Amgen 101
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 102
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 104
Roche Enters into Licensing Agreement with Amgen 105
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 106
Open Monoclonal Enters into Licensing Agreement with Amgen 107
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 108
Amgen Enters Into Licensing Agreement With R-Pharm 109
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 110
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 112
Selexis Expands License Agreement With Amgen 113
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 114
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 115
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 116
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 117
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 119
Tesaro Enters Into Licensing Agreement With Amgen 120
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 121
Equity Offering 122
Arrowhead Pharma to Raise Funds through Public Offering of Shares 122
Onyx Pharma Completes Public Offering Of Common Stock For US$358.6 Million 123
Debt Offering 124
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 124
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 126
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 128
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 130
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 132
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 134
Amgen Completes Public Offering Of Notes Due 2018 For US$736 Million 136
Amgen Completes Public Offering Of 5.50% Notes Due 2026 For US$740 Million 138
Amgen Completes Public Offering Of 5.15% Senior Notes Due 2041 For US$2.25 Billion 140
Amgen Completes Public Offering Of 3.875% Senior Notes Due 2021 For US$1.75 Billion 141
Amgen Completes Public Offering Of 1.875% Senior Notes Due 2014 For US$1 Billion 142
Amgen Completes Public Offering Of 2.5% Senior Notes Due 2016 For US$1 Billion 143
Amgen Completes Public Offering Of 4.10% Senior Unsecured Notes Due 2021 For US$1,000 Million 144
Amgen Completes Public Offering Of 2.30% Senior Unsecured Notes Due 2016 For US$750 Million 145
Amgen Completes Public Offering Of 5.65% Senior Unsecured Notes Due 2042 For US$1,250 Million 146
Asset Transactions 147
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 147
Boehringer Ingelheim Acquires Fremont Facility From Amgen 148
Acquisition 150
Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 150
Amgen to Acquire Catherex from Medigene 151
Amgen Acquires Dezima Pharma 152
Amgen Completes Acquisition of Onyx Pharma For Up To US$10.4 Billion in Tender Offer 154
Biocad Rumored To Sell Itself For Up To US$1 Billion 157
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 158
Amgen Completes Acquisition Of KAI Pharma For US$315 Million 160
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For US$700 Million 162
Amgen Completes Acquisition Of Micromet For US$1.16 Billion 164
Amgen Acquires Bergamo 166
Amgen Completes The Acquisition Of BioVex For US$1 Billion 167
Amgen Inc – Key Competitors 170
Amgen Inc – Key Employees 171
Amgen Inc – Locations And Subsidiaries 173
Head Office 173
Other Locations & Subsidiaries 173
Joint Venture 178
Recent Developments 180
Strategy And Business Planning 180
Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 180
Financial Announcements 181
Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 181
Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 183
Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 185
Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 188
Oct 27, 2016: Amgen Reports Third Quarter 2016 Financial Results 191
Jul 27, 2016: Amgen Reports Second Quarter 2016 Financial Results 194
Apr 28, 2016: Amgen’s First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 197
Jan 28, 2016: Amgen’s 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share Increased 19 Percent To $10.38 199
Corporate Communications 201
Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 201
Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 202
Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 203
Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 204
Oct 14, 2016: Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors 205
Legal and Regulatory 206
Jun 13, 2017: US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines 206
Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 207
Jul 20, 2016: Amgen Announces Settlement Of Securities Litigation 208
Government and Public Interest 209
Aug 23, 2017: Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease 209
Sep 26, 2016: Amgen Opens Nomination Process For LabCentral Residency 210
May 18, 2016: Landmark deCODE genetics Study Points to a New Mechanism that Affects Cholesterol Levels and The Risk of Heart Disease 211
May 05, 2016: NICE draft guidance recommends new drugs for cholesterol disorder 212
Product News 213
12/12/2016: Discussion on Advaxis’ ADXS-NEO Program Held During the International Congress on Immunotherapies in Cancer 213
12/05/2017: Xencor Receives Milestone Payment from Amgen 214
11/10/2017: Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer 215
11/07/2016: Amgen To Present Data On ABP 710 At ACR/ARHP 2016 Annual Meeting 216
11/07/2016: Amgen To Present Data On Denosumab At ACR/ARHP 2016 Annual Meeting 217
11/07/2016: Amgen To Present Data On Etanercept At ACR/ARHP 2016 Annual Meeting 218
11/07/2016: Amgen To Present Data Romosozumab At ACR/ARHP 2016 Annual Meeting 219
11/04/2016: FDA Approves Expanded Use Of ENBREL (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis 220
10/10/2016: New Retrospective Analyses Confirm Vectibix (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin 221
10/06/2016: Talimogene laherparepvec in melanoma: Added benefit not proven 223
10/03/2016: Study Results Published In Journal of Clinical Oncology Show BLINCYTO (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia 224
09/14/2017: FDA Approves Amgen And Allergan’s MVASI (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer 226
09/07/2016: Amgen to Highlight Abstracts on Prolia (denosumab) at American Society for Bone and Mineral Research Annual Meeting 227
09/07/2016: ONO Launches KYPROLIS for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor 229
09/01/2016: FDA Approves BLINCYTO (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia 230
07/11/2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children 231
07/04/2016: ONO Receives Manufacturing and Marketing Approval in Japan for KYPROLIS, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma 233
07/03/2017: Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe 234
06/23/2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia 235
06/09/2016: Preliminary data for pre-kidney transplant being presented June 13 236
06/03/2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers 237
05/27/2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 238
05/26/2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In “Journal of Medical Economics” 239
05/19/2016: Amgen Highlights Data on BLINCYTO at 21st Congress Of The European Hematology Association 241
05/19/2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association 242
04/19/2016: AACR Research Reception Highlights ADXS-NEO at the American Association for Cancer Research Annual Meeting 244
03/29/2017: FDA Grants Priority Review For Amgen’s BLINCYTO (blinatumomab) Supplemental Biologics License Application 245
03/23/2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-NEO at AACR Abstract 247
03/06/2017: Amgen to Present New Data on Omecamtiv Mecarbil at the American College of Cardiology 66th Annual Scientific Session 248
02/12/2016: New Drug Treatment Kyprolis (carfilzomib) for Relapsed Multiple Myeloma Launches in the UK 249
02/05/2016: Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations 251
01/16/2017: The Scottish Medicines Consortium declines two life-prolonging myeloma treatments 253
Product Approvals 254
Nov 27, 2017: Amgen Europe: Withdrawal of the Marketing Authorisation Application for Biosimilar Bevacizumab (Kyomarc) 254
Oct 09, 2017: FDA Accepts Supplemental Biologics License Application For Prolia (Denosumab) In Glucocorticoid-Induced Osteoporosis 255
Jul 31, 2017: Amgen Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 256
Jul 20, 2017: FDA Accepts Biologics License Application For Aimovig (erenumab) 257
Jun 21, 2017: Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance 258
Jun 07, 2017: Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab 260
May 18, 2017: Amgen Submits Biologics License Application To The FDA For Erenumab 261
Mar 06, 2017: Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 262
Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 263
Jan 27, 2017: Withdrawal of the application for a change to the marketing authorisation for Xgeva (denosumab) 265
Dec 19, 2016: Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan 266
Dec 02, 2016: Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab 268
Nov 15, 2016: Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration 269
Sep 30, 2016: Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma 270
Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab 271
Sep 23, 2016: Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab 272
Sep 07, 2016: ONO Submits Supplemental New Drug Application in Japan for “KYPROLIS for Intravenous Injection 10 mg and 40 mg”, a Proteasome Inhibitor, for Relapsed or Refractory Multiple Myeloma 273
Jul 21, 2016: Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA 274
Jul 03, 2016: European Commission Approves Extended Indication For Amgen’s Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients 275
May 03, 2016: FDA Grants Priority Review For Amgen’s Supplemental Biologics License Application For BLINCYTO (Blinatumoma) 277
Mar 16, 2016: NICE consults on ‘no’ recommendation for skin cancer drug talimogene laherparepvec 279
Mar 10, 2016: FDA Accepts Amgen Supplemental Biologics License Application For The Expanded Use Of Enbrel (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis 280
Mar 01, 2016: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) 281
Jan 26, 2016: NICE issues final guidance recommending etanercept for rheumatoid arthritis 282
Jan 21, 2016: FDA Approves New Kyprolis (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma 283
Jan 12, 2016: Health Canada approves Amgen’s BLINCYTO (blinatumomab) for the treatment of relapsed or refractory B-cell precursor Acute lymphoblastic leukemia 285
Clinical Trials 286
Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting 286
Jul 13, 2017: Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin (bevacizumab) 288
Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association 289
Jun 08, 2017: Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society 290
Jun 08, 2017: Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting 293
Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting 295
Apr 07, 2017: Osteoporosis drug found safe in long-term trial 296
Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 297
Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 298
Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 300
Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 301
Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy 302
Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 304
Dec 01, 2016: Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil 305
Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016 306
Nov 30, 2016: Amgen Announces Presentation Of New Data In Multiple Myeloma At ASH 2016 307
Nov 30, 2016: The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure 308
Nov 16, 2016: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study 310
Nov 14, 2016: Arrowhead Pharmaceuticals Presents New Data on ARC-LPA Using DPCsq Subcutaneous RNAi Delivery Vehicle 311
Nov 14, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the AHA Annual Scientific Meeting 312
Nov 12, 2016: Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis 313
Nov 11, 2016: UCB Presents Data on romosozumab at 2016 ACR/ARHP Annual Meeting 315
Nov 07, 2016: Cytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2016 316
Oct 20, 2016: Amgen Announces Positive Top-Line Results From XGEVA (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients 317
Oct 05, 2016: Amgen Presents Data on Vectibix (Panitumumab) At The European Society For Medical Oncology 2016 Congress 318
Oct 05, 2016: Amgen To Present Data On IMLYGIC (talimogene laherparepvec) At The European Society For Medical Oncology 2016 Congress 319
Sep 28, 2016: Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study 320
Sep 27, 2016: Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients 321
Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting 322
Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis 323
Sep 15, 2016: Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine 325
Sep 15, 2016: Novartis announces new positive data showing AMG 334 significantly reduces monthly migraine days in chronic migraine vs placebo 327
Sep 14, 2016: Amgen present erenumab at webcast call 329
Sep 14, 2016: Amgen to present romosozumab at Investor Call 330
Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting 331
Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting 332
Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development 334
Aug 29, 2016: Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia (Denosumab) In Patients Receiving Glucocorticoid Therapy 335
Jul 21, 2016: Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer 336
Jun 10, 2016: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 338
Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 339
Jun 08, 2016: Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine 343
Jun 08, 2016: UCB presents Phase 3 data from the STRUCTURE study of Romosozumab at the Annual European Congress of Rheumatology (EULAR 2016) 344
Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 345
May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress 347
May 18, 2016: Amgen To Present Data on IMLYGIC (talimogene laherparepvec) At ASCO 2016 348
May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 349
May 18, 2016: Amgen To Present Data on Vectibix (panitumumab) At ASCO 2016 350
May 18, 2016: Amgen To Presented Data on ABP 215 At ASCO 2016 351
May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 352
May 06, 2016: Arrowhead Pharmaceuticals’ Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration 353
Apr 04, 2016: Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure 354
Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide 355
Mar 30, 2016: Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment 357
Mar 20, 2016: Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis 358
Mar 04, 2016: Southampton experts trial new drug to help immune system fight cancer 359
Feb 24, 2016: Cancer Research UK launches trial for potential new drug that could help immune system fight cancer 360
Feb 21, 2016: Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis 361
Feb 10, 2016: Finding the best treatment for bowel cancer patients 363
Feb 04, 2016: Phase 3 Study of BLINCYTO (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 364
Jan 23, 2016: Vectibix (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer 365
Other Significant Developments 367
Oct 06, 2017: Amgen And LabCentral Open Nomination Process For Lab Residency 367
Sep 25, 2017: Amgen Provides Update On Hurricane Maria 368
Sep 06, 2016: Syngene International Commissions Dedicated R&D Center for Amgen 369
Appendix 370
Methodology 370
About GlobalData 370
Contact Us 370
Disclaimer 370

List of Tables
Amgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Amgen Inc, Deals By Therapy Area, 2011 to YTD 2017 16
Amgen Inc, Medical Devices Deals, 2011 to YTD 2017 18
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 26
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD479 Million 27
Amgen Completes Acquisition Of Dublin Sterile Plant From Pfizer 29
Amgen Reacquires Rights Of Its Products From Hypermarcas 31
Immatics Biotech Raises USD58 Million in Series E Financing 32
SiteOne Therapeutics Raises USD15 Million in Series B Financing 33
Dezima Pharma Raises US$13 Million In Series A Financing 34
Dezima Pharma Raises Funds Through Seed Financing 35
Gamida Cell Raises US$10 Million In Series E Financing 36
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 38
Amgen Enters into Research Agreement with Boston Children's Hospital 39
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 40
Amgen and Simcere Pharma Enter into Co-Development Agreement 41
Amgen and Array BioPharma Enter into Agreement 42
Elasmogen, Feldan Bio Enter into Agreement with Amgen 43
SiteOne Therapeutics Enters into R&D Agreement with Amgen 44
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 45
Nuevolution Enters into Research Agreement with Amgen 46
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 47
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 48
Amgen Forms Partnership with Advaxis 49
Amgen Enters into Agreement with Allergan 50
Amgen and Daiichi Sankyo Enter into Agreement 51
Flatiron Health Partners with Amgen 52
Amgen and Merck Enter into Agreement 53
Amgen Expands its Co-Development Agreement with Novartis 54
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen 55
Amgen Enters into Research Agreement with MD Anderson 56
Innovative Targeting Solutions Enters into Research Agreement with Amgen 57
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 58
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 60
Amgen and Astellas Pharma Form Joint Venture 61
Amgen Forms Joint Venture With Zhejiang Beta Pharma 62
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 64
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 65
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 66
Amgen Enters Into Co-Development Agreement With Astellas 67
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 68
PeptiDream Expands Drug Discovery Agreement with Amgen 69
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 70
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 71
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 72
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 73
Dako Enters Into Co-Development Agreement With Amgen 75
Dako Enters Into Co-Development Agreement With Amgen 76
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 77
Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 79
deCODE genetics Enters Into Research Agreement With Pfizer 80
Micromet Enters Into Research Agreement With Amgen For BiTE Antibodies 81
S*Bio Amends Collaboration With Onyx Pharma 82
AstraZeneca Rumored To Merge With Amgen 83
Amgen Enters into Licensing Agreement with Carmot Therapeutics 84
Amgen Enters into Licensing Agreement with Ligand Pharma 85
Amgen Enters into Licensing Agreement with Immatics Biotech 86
Amgen Enters into Licensing Agreement with Teijin Pharma 87
Amgen Enters into Licensing Agreement with Arrowhead Pharma 88
Amgen Enters into Licensing Agreement with Xencor 89
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 90
FLX Bio Enters Into Licensing Agreement with Amgen 91
Celimmune Enters into Licensing Agreement with Amgen for AMG 714 92
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 93
Amgen Enters into Licensing Agreement with Kite Pharma 94
Cancer Research UK Enters into Licensing Agreement with Amgen 96
Amgen Expands its Licensing Agreement with Carmot Therapeutics 97
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 98
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 100
Atara Biotherapeutics Enters Into Licensing Agreement with Amgen 101
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 102
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 104
Roche Enters into Licensing Agreement with Amgen 105
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 106
Open Monoclonal Enters into Licensing Agreement with Amgen 107
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 108
Amgen Enters Into Licensing Agreement With R-Pharm 109
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 110
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 112
Selexis Expands License Agreement With Amgen 113
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 114
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 115
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 116
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 117
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 119
Tesaro Enters Into Licensing Agreement With Amgen 120
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 121
Arrowhead Pharma to Raise Funds through Public Offering of Shares 122
Onyx Pharma Completes Public Offering Of Common Stock For US$358.6 Million 123
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 124
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 126
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 128
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 130
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 132
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 134
Amgen Completes Public Offering Of Notes Due 2018 For US$736 Million 136
Amgen Completes Public Offering Of 5.50% Notes Due 2026 For US$740 Million 138
Amgen Completes Public Offering Of 5.15% Senior Notes Due 2041 For US$2.25 Billion 140
Amgen Completes Public Offering Of 3.875% Senior Notes Due 2021 For US$1.75 Billion 141
Amgen Completes Public Offering Of 1.875% Senior Notes Due 2014 For US$1 Billion 142
Amgen Completes Public Offering Of 2.5% Senior Notes Due 2016 For US$1 Billion 143
Amgen Completes Public Offering Of 4.10% Senior Unsecured Notes Due 2021 For US$1,000 Million 144
Amgen Completes Public Offering Of 2.30% Senior Unsecured Notes Due 2016 For US$750 Million 145
Amgen Completes Public Offering Of 5.65% Senior Unsecured Notes Due 2042 For US$1,250 Million 146
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 147
Boehringer Ingelheim Acquires Fremont Facility From Amgen 148
Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 150
Amgen to Acquire Catherex from Medigene 151
Amgen Acquires Dezima Pharma 152
Amgen Completes Acquisition of Onyx Pharma For Up To US$10.4 Billion in Tender Offer 154
Biocad Rumored To Sell Itself For Up To US$1 Billion 157
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 158
Amgen Completes Acquisition Of KAI Pharma For US$315 Million 160
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For US$700 Million 162
Amgen Completes Acquisition Of Micromet For US$1.16 Billion 164
Amgen Acquires Bergamo 166
Amgen Completes The Acquisition Of BioVex For US$1 Billion 167
Amgen Inc, Key Competitors 170
Amgen Inc, Key Employees 171
Amgen Inc, Other Locations 173
Amgen Inc, Subsidiaries 175
Amgen Inc, Joint Venture 178

★海外企業調査レポート[Amgen Inc (AMGN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Sixt SE：企業の戦略・SWOT・財務情報
    Sixt SE - Strategy, SWOT and Corporate Finance Report Summary Sixt SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Ambry Genetics Corp：医療機器：M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • DHX Media Ltd.：企業のM&A・事業提携・投資動向
    DHX Media Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DHX Media Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Sumitomo Dainippon Pharma Co Ltd (4506)：製薬・医療：M&Aディール及び事業提携情報
    Summary Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, …
  • Sberbank of Russia：企業の戦略・SWOT・財務情報
    Sberbank of Russia - Strategy, SWOT and Corporate Finance Report Summary Sberbank of Russia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hilton Worldwide Holdings Inc：企業の戦略・SWOT・財務情報
    Hilton Worldwide Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Hilton Worldwide Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • New China Life Insurance Company Ltd.：企業のM&A・事業提携・投資動向
    New China Life Insurance Company Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New China Life Insurance Company Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Genfit SA (GNFT)：企業の財務・戦略的SWOT分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, biomarkers, TGFTX1 and TGFTX4. Its TGFTX1 is a research program …
  • Schuler AG：企業の戦略・SWOT・財務情報
    Schuler AG - Strategy, SWOT and Corporate Finance Report Summary Schuler AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Austrian Post：企業の戦略・SWOT・財務情報
    Austrian Post - Strategy, SWOT and Corporate Finance Report Summary Austrian Post - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Canadian Broadcasting Corp：企業の戦略的SWOT分析
    Canadian Broadcasting Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Eastman Chemical Co (EMN)：企業の財務・戦略的SWOT分析
    Eastman Chemical Co (EMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Zotefoams plc (ZTF)：企業の財務・戦略的SWOT分析
    Summary Zotefoams plc (Zotefoams) is a chemical manufacturer that markets cross-linked block foams. The company offers products such as microzote, zotek F, zotek N, T tubes, plastazote, evazote, zotek peba foam, supazote, and others. It offers services such as manufacturing and distribution services …
  • AnaBios Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary AnaBios Corp (AnaBios) is a pre-clinical stage contract research organization that offers drug efficacy studies on human samples. The organization’s products portfolio includes human dorsal root ganglia neuron cultures, human cardiac mesenchymal stem cells, human heart tissue samples, human …
  • Windtree Therapeutics Inc (WINTD)：企業の財務・戦略的SWOT分析
    Windtree Therapeutics Inc (WINTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ascom Holding AG：企業のM&A・事業提携・投資動向
    Ascom Holding AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ascom Holding AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Albireo Pharma Inc (ALBO)：医療機器：M&Aディール及び事業提携情報
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe med …
  • Buzzi Unicem SpA：戦略・SWOT・企業財務分析
    Buzzi Unicem SpA - Strategy, SWOT and Corporate Finance Report Summary Buzzi Unicem SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • KARL STORZ SE & Co KG：企業の戦略的SWOT分析
    KARL STORZ SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Hitachi Construction Machinery Co., Ltd. (6305)：企業の財務・戦略的SWOT分析
    Hitachi Construction Machinery Co., Ltd. (6305) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆